Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors.

ABSTRACT:

Background

This study compared the clinical efficacy of first-, second-, and third-generation tyrosine kinase inhibitors (TKIs) in previously untreated non-small cell lung cancer (NSCLC) patients harboring uncommon epidermal growth factor receptor (EGFR) exon 19delins variants.

Methods

We retrospectively analyzed the clinical outcomes of NSCLC patients with EGFR exon 19delins mutations who were treated with third- and first-generation EGFR TKIs. In vitro and in vivo studies were conducted to verify the sensitivity of these mutations to distinct generations of TKIs. Molecular simulation was used to investigate the structural characteristics of the EGFR mutant molecules.

Results

In a multicenter cohort of 1,526 patients, 37 (2.4 %) had uncommon EGFR 19delins mutations.

SUBMITTER: Lu Z 

PROVIDER: S-EPMC10728704 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature